Eton licenses Baylor patent rights for ET-900 epileptic spasms development program
Eton Pharmaceuticals announced ET-900, a new development program evaluating its mecasermin injection, the active ingredient in INCRELEX, for infantile and epileptic spasms, and said it licensed related patent rights from Baylor College of Medicine. A research Investigational New Drug application has been submitted to the FDA for an investigator-sponsored Phase 2 study, with initial enrollment and dosing targeted for the first quarter of 2027. The filing contains no financial figures, so its near-term financial effect is not quantified, and Eton retains commercial rights to ET-900 according to the press release.
Key points
- Research IND submitted to the FDA for an investigator-sponsored Phase 2 study of mecasermin in children with refractory epileptic spasms
- Study expected to enroll up to 20 patients ages 2–18 across three sites: University of Chicago, Baylor College of Medicine, and UCLA
- Initial enrollment and patient dosing targeted for the first quarter of 2027
- Preclinical animal data cited in the press release showed approximately 50% reduction in daily spasm counts
The filing
Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 02, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.